Received Apr 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | UNK | UNK | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 324BY | — |
Interchangeability (first dose: TWINRIX, second dose: HEPLISAV).; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of interchange of vaccine products in a 63-year-old male patient who received HAB (Twinrix) (batch number 324BY, expiry date 28-AUG-2026) for prophylaxis. Co-suspect products included Hepatitis b vaccine rHBsAg (yeast) (Heplisav b) for prophylaxis. On 11-MAR-2025, the patient received the 1st dose of Twinrix. On 08-APR-2025, the patient received Heplisav b. On an unknown date, an unknown time after receiving Twinrix, the patient experienced interchange of vaccine products (Verbatim: Interchangeability (first dose: TWINRIX, second dose: HEPLISAV).). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date : 11-APR-2025 Other HCP reported a patient received a first dose of Twinrix, and afterwards received an Heplisav dose, which led to interchange of vaccine products. Reporter asked for any advice in this situation.